Immunotherapies for chronic inflammation
3B +
humans live with chronic inflammatory diseases
The Market
2
400M +
pets live with chronic inflammatory diseases
Current focus Market
3
$2B +
Dog/cat OA chronic pain
$3B +
Dog/cat atopic dermatitis
$5B +
TOTA
4
Click to �start the video
Our Solution
Novel first-in-class immunotherapy
to reduce
neurogenic inflammation
in chronic conditions
(
(
5
Our Technology
targets neurogenic inflammation
Inject fusion protein
Production of neutralizing antibodies
Antibodies neutralize inflammatory mediators
Happy dog
6
Xep01 – Dog OA Chronic Pain
Target
Identification
Preclinical
Studies
POC Clinical Trials
Clinical Trials
Registration
Xep02 – Dog Atopic Dermatitis
Xep03 – Feline OA Chronic Pain
Xep04 – Feline Atopic Dermatitis
Our pipeline
7
POC trial results available
POC trial results available
Xep05 – Dog Senescence
Our Solution
IMPROVE Function & Mobility�REDUCE Pain & Inflammation�REDUCE Medication Intake
8
Why is this important?
mAbs
Once a month
$50 to $100/dose
Xeptiva
Admin every 6-8 months �(after initial protocol)
$30/dose (to end user)
Multi-target approach
Might lose efficacy over time
NSAIDs
Affordable
30 days max or side effects
Once a day
9
FOCUS
GTM Strategy
REGULATORY
STRATEGY
1st: OA Chronic Pain product
FDA CVM
Latam market 1st (2025)�as we conduct clinical trials in US & EU for 2027 approval
Business Model
B2B
Sublicence Xep01, Xep02, etc
Large animal health companies�(currently in conversations with the top 5)
Our Leadership
CEO
Innovation expert
JOSEFINA CORREA, MS, PMP
EMILIANO TRIAS, PHD
LUIS BARBEITO, MD
CSO
Neuroscience & aging specialist
CSO
Neuropharmacology expert
12
Our Advisors
COMMERCIAL ADVISORS
AgTech Advisors
TONY SIMPSON
SERGIO FOGEL
KEITH HOFFMAN
dLocal & Angel Investor
Athos Therapeutics
SCIENTIFIC & CLINICAL ADVISORS
NC State University
DUNCAN LASCELLES
JOSEPH BECKMAN
CORINNA BEALE
eMSion
Tuft University
13
www.xeptiva.com
Contact: jcorrea@xeptiva.com